Benzimidazole compounds and derivatives as EGFR inhibitors

US11174245B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Dietrich BOESE · Erzhausen, DE
• Georg Dahmann · Biberach an der Riß, DE
• Harald Engelhardt · Ebreichsdorf, AT
• Mark PETRONCZKI · Wien, AT
• Dirk Scharn · Wien, AT

Key dates

• Filing date: Feb 20, 2019
• Grant date: Nov 16, 2021
• Expiry date: Feb 20, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.